Literature DB >> 11598162

Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer.

J J Ascaño1, H Frierson, C A Moskaluk, J C Harper, F Roviello, C E Jackson, W El-Rifai, C Vindigni, P Tosi, S M Powell.   

Abstract

Loss of the cell adhesion molecule E-cadherin has been observed in a variety of human carcinomas, and germline E-cadherin mutations have been found in several familial cases of diffuse gastric cancer. We sought to determine the prevalence and nature of E-cadherin alterations in "sporadic" gastric carcinomas. We performed comprehensive sequencing of the coding region, loss of heterozygosity (LOH) analysis, and immunohistochemical protein expression determination on 40 sporadic gastric adenocarcinomas. In total, 7 of 25 diffuse-type cancers harbored genetic alterations in the E-cadherin gene. Novel mutations predicted to significantly compromise protein function were found within 4 of these cancers, 2 of which harbored alterations resulting in biallelic inactivation of the gene product. Three diffuse cancers failed to amplify Exon 8 of E-cadherin, suggesting the presence of a homozygous abnormality. Notably, one germline E-cadherin mutation was also identified within these "sporadic" diffuse cancers. Significant gene mutations were not found in the 14 intestinal-type or histologically mixed cancer. Immunohistochemistry revealed aberrant or negative protein expression in seven diffuse-type tumors, four of which correlated with the genetic alterations. Both diffuse and intestinal-type tumors exhibited low rates of LOH, suggesting that allelic loss at the locus is not a common mechanism for E-cadherin inactivation during gastric tumorigenesis. Our observations suggest that inactivation of the E-cadherin gene occurs only in a subset of diffuse-type gastric cancers, as the majority of cases did not contain genetic alterations or identifiable protein abnormalities. Germline E-cadherin alterations, although rare, may underlie some diffuse gastric cancer cases that have important biologic and practical implications

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11598162     DOI: 10.1038/modpathol.3880416

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  14 in total

1.  Mutation analysis of APC gene in gastric cancer with microsatellite instability.

Authors:  Dian-Chun Fang; Yuan-Hui Luo; Shi-Ming Yang; Xiao-An Li; Xian-Long Ling; Li Fang
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

Review 2.  Gastric adenocarcinoma: review and considerations for future directions.

Authors:  Bryan J Dicken; David L Bigam; Carol Cass; John R Mackey; Anil A Joy; Stewart M Hamilton
Journal:  Ann Surg       Date:  2005-01       Impact factor: 12.969

3.  Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas.

Authors:  Yao-Chi Liu; Chen-Yang Shen; Hurng-Sheng Wu; Tsai-Yuan Hsieh; De-Chuan Chan; Cheng-Jueng Chen; Jyh-Cherng Yu; Cheng-Ping Yu; Horng-Jyh Harn; Peng-Jen Chen; Chung-Bao Hsieh; Teng-Wei Chen; Huan-Mieng Hsu
Journal:  World J Gastroenterol       Date:  2006-04-14       Impact factor: 5.742

4.  A protein and mRNA expression-based classification of gastric cancer.

Authors:  Namrata Setia; Agoston T Agoston; Hye S Han; John T Mullen; Dan G Duda; Jeffrey W Clark; Vikram Deshpande; Mari Mino-Kenudson; Amitabh Srivastava; Jochen K Lennerz; Theodore S Hong; Eunice L Kwak; Gregory Y Lauwers
Journal:  Mod Pathol       Date:  2016-04-01       Impact factor: 7.842

5.  Mitochondrial microsatellite instability in gastric cancer and its precancerous lesions.

Authors:  Xian-Long Ling; Dian-Chun Fang; Rong-Quan Wang; Shi-Ming Yang; Li Fang
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742

6.  Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Authors:  Birgit Luber; Joëlle Deplazes; Gisela Keller; Axel Walch; Sandra Rauser; Martin Eichmann; Rupert Langer; Heinz Höfler; Susanna Hegewisch-Becker; Gunnar Folprecht; Ewald Wöll; Thomas Decker; Esther Endlicher; Sylvie Lorenzen; Falko Fend; Christian Peschel; Florian Lordick
Journal:  BMC Cancer       Date:  2011-12-07       Impact factor: 4.430

7.  A short guide to hereditary diffuse gastric cancer.

Authors:  Parry Guilford; Vanessa Blair; Helen More; Bostjan Humar
Journal:  Hered Cancer Clin Pract       Date:  2007-12-15       Impact factor: 2.857

8.  Mouse gastric tumor models with prostaglandin E2 pathway activation show similar gene expression profiles to intestinal-type human gastric cancer.

Authors:  Hiraku Itadani; Hiroko Oshima; Masanobu Oshima; Hidehito Kotani
Journal:  BMC Genomics       Date:  2009-12-17       Impact factor: 3.969

9.  E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors.

Authors:  Eike Burandt; Felix Lübbersmeyer; Natalia Gorbokon; Franziska Büscheck; Andreas M Luebke; Anne Menz; Martina Kluth; Claudia Hube-Magg; Andrea Hinsch; Doris Höflmayer; Sören Weidemann; Christoph Fraune; Katharina Möller; Frank Jacobsen; Patrick Lebok; Till Sebastian Clauditz; Guido Sauter; Ronald Simon; Ria Uhlig; Waldemar Wilczak; Stefan Steurer; Sarah Minner; Rainer Krech; David Dum; Till Krech; Andreas Holger Marx; Christian Bernreuther
Journal:  Biomark Res       Date:  2021-06-05

10.  Exome sequencing identifies early gastric carcinoma as an early stage of advanced gastric cancer.

Authors:  Guhyun Kang; Woo Cheol Hwang; In-Gu Do; Kai Wang; So Young Kang; Jeeyun Lee; Se Hoon Park; Joon Oh Park; Won Ki Kang; Jiryeon Jang; Min-Gew Choi; Jun Ho Lee; Tae Sung Sohn; Jae Moon Bae; Sung Kim; Min Ji Kim; Seonwoo Kim; Cheol Keun Park; Kyoung-Mee Kim
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.